Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: A retrospective study of alectinib versus ceritinib in patients with advanced non–small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed

Fig. 3

a The relationship between PFS of crizotinib and subsequent alectinib/ceritinib in patients who underwent drug resistance in the two lines of treatment. b Cumulative incidence of systemic progression (black) and CNS progression (red) between the alectinib (solid line) and ceritinib (broken line) treatment

Back to article page
\